HLS Therapeutics Inc. (HLTRF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

HLS Therapeutics Inc. (HLTRF) Healthcare & Pipeline Overview

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring and commercializing treatments for central nervous system and cardiovascular disorders across Canada, the United States, and internationally. Its product portfolio includes treatments for schizophrenia and cardiovascular diseases, positioning it in a competitive yet growing market.

What Is the Investment Thesis for HLTRF?

HLS Therapeutics Inc. presents a focused investment opportunity within the specialty pharmaceutical sector, targeting CNS and cardiovascular markets. With a market capitalization of $86.9M, the company's growth potential hinges on the successful commercialization of its key products, including Clozaril, Vascepa, and PERSERIS. A gross margin of 71.9% indicates strong pricing power, but a negative profit margin of -22.3% highlights the need for improved operational efficiency. Upcoming catalysts include potential expansion of its product portfolio through strategic acquisitions and geographic expansion. Potential risks include competition from generic drug manufacturers and the need for continuous innovation to maintain market share. The company's beta of 0.84 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

HLTRF Key Highlights

Market capitalization of $86.9M reflects its position as a smaller player in the specialty pharmaceutical market.

• Gross margin of 71.9% indicates strong pricing power and efficient cost management in product sales.
• Negative P/E ratio of -8.44 due to current losses, suggesting potential for future earnings growth.
• Profit margin of -22.3% highlights the need for improved operational efficiency and cost control.
• Beta of 0.84 indicates lower volatility compared to the overall market, potentially appealing to risk-averse investors.

Who Are HLTRF's Competitors?

HLTRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HLTRF's Key Strengths?

Portfolio of established pharmaceutical products.

• Focus on specialized therapeutic areas (CNS and cardiovascular).
• Geographic presence in Canada, the US, and internationally.
• High gross margin indicates strong pricing power.

What Are HLTRF's Weaknesses?

Negative profit margin indicates operational inefficiencies.

• Reliance on acquired products for revenue growth.
• Limited internal research and development capabilities.
• Small market capitalization compared to major pharmaceutical companies.

What Could Drive HLTRF Stock Higher?

Commercialization of existing pharmaceutical products (Clozaril, Vascepa, PERSERIS) driving revenue growth.

• Potential strategic acquisitions to expand product portfolio and geographic reach.
• Expansion of Vascepa market through increased awareness and adoption.
• Development of novel drug delivery systems to improve product efficacy.
• Personalized medicine approaches using diagnostic tools to improve treatment outcomes.

What Are the Key Risks for HLTRF?

Financial-distress signal — its Altman Z-Score of -1.17 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-16.5%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Competition from generic drug manufacturers eroding market share.
• Patent expiration of key products impacting revenue streams.
• Regulatory changes and pricing pressures affecting profitability.
• Product liability risks associated with pharmaceutical products.
• Operational inefficiencies leading to negative profit margins.

What Are the Growth Opportunities for HLTRF?

• Expansion of Vascepa Market: HLS Therapeutics has the opportunity to expand the market for Vascepa, a treatment for cardiovascular risk reduction. The market for cardiovascular drugs is substantial, with a global market size estimated at hundreds of billions of dollars. By increasing awareness and adoption of Vascepa among healthcare providers and patients, HLS Therapeutics can drive revenue growth in the coming years. This expansion can be achieved through targeted marketing campaigns, clinical trials demonstrating the drug's efficacy, and strategic partnerships with key opinion leaders.
• Strategic Acquisitions: HLS Therapeutics can pursue strategic acquisitions to expand its product portfolio and geographic reach. The specialty pharmaceutical market is ripe with opportunities to acquire promising drug candidates and commercialized products. By identifying and acquiring companies with complementary therapeutic focuses and geographic footprints, HLS Therapeutics can diversify its revenue streams and reduce its reliance on individual products. These acquisitions can be financed through a combination of debt and equity, with a focus on maintaining a healthy balance sheet.
• Geographic Expansion: HLS Therapeutics has the opportunity to expand its geographic presence beyond Canada and the United States. Emerging markets in Asia, Latin America, and Eastern Europe offer significant growth potential for specialty pharmaceutical products. By establishing partnerships with local distributors and navigating regulatory pathways, HLS Therapeutics can tap into these underserved markets and drive revenue growth. This expansion requires careful planning and execution, with a focus on understanding local market dynamics and regulatory requirements.
• Development of Novel Drug Delivery Systems: HLS Therapeutics can invest in the development of novel drug delivery systems to improve the efficacy and patient compliance of its existing products. For example, the company could explore the development of extended-release formulations or injectable delivery systems for its CNS drugs. These innovations can differentiate HLS Therapeutics' products from competitors and create a competitive advantage. The market for drug delivery systems is growing rapidly, driven by the increasing demand for more convenient and effective drug therapies.
• Focus on Personalized Medicine: HLS Therapeutics can leverage its MyCare psychiatry lab assays and MyCare Insite point-of-care therapeutic drug-level monitoring tests to personalize treatment for patients with CNS disorders. By using these diagnostic tools to identify patients who are most likely to respond to specific treatments, HLS Therapeutics can improve treatment outcomes and reduce healthcare costs. The market for personalized medicine is growing rapidly, driven by advancements in genomics and proteomics. HLS Therapeutics is well-positioned to capitalize on this trend.

What Are HLTRF's Competitive Advantages?

• Proprietary rights to acquired pharmaceutical products.
• Established distribution network in key markets.
• Specialized expertise in CNS and cardiovascular therapeutics.
• Brand recognition for key products like Clozaril and Vascepa.

What Does HLTRF Do?

Founded in 2018 and headquartered in Etobicoke, Canada, HLS Therapeutics Inc. operates as a specialty pharmaceutical company acquiring and commercializing pharmaceutical products. The company focuses on the specialty central nervous system (CNS) and cardiovascular (CV) markets across Canada, the United States, and internationally. HLS Therapeutics' portfolio includes Clozaril, an atypical antipsychotic used in schizophrenia treatment; Vascepa, an icosapent ethyl capsule; and PERSERIS, an injectable risperidone product also for schizophrenia. Additionally, HLS Therapeutics offers MyCare psychiatry lab assays and MyCare Insite point-of-care therapeutic drug-level monitoring tests. The company also holds U.S. marketing rights for Absorica, a dermatology product, Canadian rights for Trinomia in CV therapeutics, and a portfolio of royalty interests in four healthcare products. HLS Therapeutics aims to address unmet medical needs in its therapeutic areas through strategic acquisitions and commercialization efforts.

What Products and Services Does HLTRF Offer?

• Acquires and commercializes pharmaceutical products.
• Focuses on the central nervous system (CNS) market.
• Offers treatments for schizophrenia.
• Provides cardiovascular (CV) therapeutics.
• Offers psychiatry lab assays for therapeutic drug monitoring.
• Markets dermatology products.

How Does HLTRF Make Money?

• Acquires rights to existing pharmaceutical products.
• Commercializes products through sales and marketing efforts.
• Generates revenue through product sales in Canada, the US, and internationally.
• Offers diagnostic services to complement pharmaceutical treatments.

What Industry Does HLTRF Operate In?

HLS Therapeutics Inc. operates within the specialty pharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in drug delivery technologies. Key trends include the rise of biosimilars, personalized medicine, and digital health solutions. HLS Therapeutics competes with both large pharmaceutical companies and smaller specialty players, focusing on niche markets within CNS and cardiovascular therapeutics. The company's success depends on its ability to innovate, acquire promising drug candidates, and effectively commercialize its products.

Who Are HLTRF's Key Customers?

• Patients with central nervous system disorders (e.g., schizophrenia).
• Patients with cardiovascular diseases.
• Psychiatrists and other healthcare providers.
• Pharmacies and hospitals.

Company Profile

HLS Therapeutics Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Etobicoke, CA. The company is led by CEO Craig Stuart Millian. HLTRF has traded publicly since 2010.

HLS Therapeutics Inc. Financial Trajectory

HLS Therapeutics Inc. (HLTRF) reported $12.7M in revenue for Q1 2026, a decline of 17.8% compared to the prior quarter. The company recorded a net loss of $2.3M, with diluted EPS of $-0.07. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, HLTRF averaged $-0.08 in diluted EPS.

How HLS Therapeutics Inc. Is Valued

HLS Therapeutics Inc. carries a market capitalization of $86.9M, placing it in the micro-cap category. Relative to its peer group, HLTRF's quantitative score of 48/100 is roughly in line with the peer average of 44/100.

Return on equity for HLS Therapeutics Inc. stands at -16.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 19.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.0%, the inverse of the P/E and a quick read on earnings relative to price.

HLS Therapeutics Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.17 places it in the distress zone, a signal of elevated financial risk.

HLS Therapeutics Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 11.5% below estimates on average.

Wall Street analysts project HLS Therapeutics Inc. revenue of about $57.8M for fiscal 2026, with EPS near $-0.25. The estimate reflects 4 contributing analysts.

HLTRF Financials

HLTRF Latest News

HLTRF Analyst Consensus

HLTRF MoonshotScore

Common Questions About HLTRF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources